Mytesi
Dosing

DosingDigital2022-09-30T21:15:06+00:00

Mytesi is a 125-mg delayed-release
tablet taken twice per day¹

Mytesi is taken orally
with or without food¹

TABLETS SHOULD BE
SWALLOWED WHOLE¹

Mytesi tablets should not
be crushed or chewed¹

Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen.¹

Reference:
1. Mytesi [package insert]. San Francisco, CA: Napo Pharmaceuticals. 2018.

For product information and inquiries or to report an adverse event, please contact the Mytesi Call Center at (844) 722-8256 or by email at product.inquiries@napopharma.com

Read Important Safety Information about Mytesi

VIEW MORE +

VIEW LESS −

Mytesi (crofelemer) is an antidiarrheal drug indicated for symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS who are on antiretroviral therapy (ART)

Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (6%), bronchitis (4%), cough (4%), flatulence (3%), and increased bilirubin (3%).

Please See Full Prescribing Information

Mytesi Dosing

Mytesi is a 125-mg delayed-release tablet taken twice per day1

Mytesi may reduce noninfectious diarrhea in PLWH on ART.

Mytesi is well tolerated.

Learn about NapoCaresTM.

Read Important Safety Information about Mytesi

Read Important Safety Information about Mytesi

Mytesi
Dosing

Mytesi is a 125-mg delayed-release
tablet taken twice per day¹

Mytesi may reduce
noninfectious diarrhea
in PLWH on ART.

Mytesi
is well tolerated.

Learn
about NapoCares^TM.